RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

September 11, 2025 8:30 AM

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA.Event Information:EventNanoViricides Presentation at the LSX World Congress, 2025, Boston, MADay & DateWednesday,...

Read more

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

September 11, 2025 8:30 AM

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the "Existing Warrants"), at the existing exercise price of $2.20 per share....

Read more

Avel eCare's Dr. Kelly Rhone to Speak on Rural Health Panel at ATA Annual Conference

September 11, 2025 8:12 AM

Avel eCare today announced that Dr. Kelly Rhone, Chief Medical Officer, will speak on a featured panel at the American Telemedicine Association (ATA) Annual Conference on Wednesday, September 17th, 2025.The panel will explore challenges and innovations in delivering care to underserved and rural communities-an area where Dr. Rhone has built a national reputation as a physician leader. At Avel, she oversees a broad spectrum of clinical...

Read more

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

September 11, 2025 8:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the submission of an application to the European Medicines Agency (EMA) by Johnson & Johnson seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis...

Read more

Luminous Global Announces 4th Annual Light Up the Night: "The Enchanted Garden" to Benefit the Luminous Advocacy Project

September 11, 2025 6:00 AM

Luminous Global announces the 4th Annual Light Up the Night gala, themed "The Enchanted Garden," an unforgettable evening dedicated to advocacy, awareness, and empowerment. The event will take place on Friday, September 26, 2025, from 6:30 p.m. to 11:30 p.m. at the iconic Mayfair House Hotel & Garden in Coconut Grove, Miami.Guests will be welcomed into a magical garden setting, illuminated by candlelight and enhanced by live music, inspiring...

Read more

Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit

September 11, 2025 3:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the upcoming DCNY Summit, taking place in Washington, DC on 18 September 2025 and in New York on 22 September 2025.The DCNY Summit is co-hosted by the Alliance Indus Foundation, together with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners, and is designed as a...

Read more

Cantargia Closes the Acquisition of CAN10 by Otsuka

September 11, 2025 1:50 AM

Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's acquisition of the anti-IL1RAP antibody program CAN10 from Cantargia. Cantargia will thus receive an upfront payment of USD 33 million.On July 15, 2025, Cantargia announced that an agreement had been entered regarding the acquisition of the IL1RAP antibody program CAN10 by Otsuka. The...

Read more

Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025

September 10, 2025 4:30 PM

Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011...

Read more

AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 2025

September 10, 2025 4:00 PM

AGFA HealthCare has been recognized by KLAS Research for significant satisfaction gains. Customer satisfaction with AGFA's Enterprise Imaging VNA and XERO® Viewer has increased significantly over the past 18 months, with both solutions named Best in KLAS 2025 winners.Report highlights:Significant Gains: customer satisfaction with AGFA's VNA increased by 13 points on a 100-point scale over the past 18 months - the largest improvement in the...

Read more

Pharma Executives Redefine IT Priorities: Five Stats Signal Urgent Tech Shift

September 10, 2025 2:30 PM

Black Book Research today released results from a proprietary series of industry sector studies conducted in Q2-Q3 2025. Based on responses from 339 senior leaders across biopharmaceutical manufacturers, contract research organizations (CROs), specialty pharma companies, and academic medical research centers, the studies capture the sharp pivot executives are making toward digital health, R&D cybersecurity, and advanced data infrastructure as...

Read more

Neon Parody Labs Launches GENOMIRATHEON(TM): Treaty-Filed DNA Licensing Rail with 461 Licenses

September 10, 2025 12:45 PM

Neon Parody Labs today announced the launch of GENOMIRATHEON™, a new DNA licensing platform that transforms gene activity into legally recognised, trackable records.By linking biology directly with licensing rights, payments, and compliance systems, the platform introduces a new way to create legal and financial records through gene activity.The technology, developed by Neon Parody Labs works by detecting the natural signals released when a gene...

Read more

Virtual Care Crosses the Threshold: AI Delivers 23% Average Impact in U.S. Hospitals

September 10, 2025 12:00 PM

Black Book Research today announced the release of The State of AI-Enabled Virtual Care in U.S. Healthcare, a comprehensive 90-page report now available for download at no cost to industry stakeholders. The study, based on an August 2025 survey of 554 verified clinical, finance, and IT leaders, confirms that virtual nursing and allied virtual care are no longer experimental:73% of respondents expect their organizations to expand virtual care by...

Read more

Diabetics Trust Expands Access with Secure Nationwide Platform for Selling Diabetic Supplies

September 10, 2025 11:30 AM

Rising healthcare costs and the growing issue of unused medical products have left many Americans searching for safe and legal ways to manage their surplus diabetic supplies. Diabetics Trust, a leading nationwide diabetic supply buyback program, has launched an easier and more transparent way for individuals and caregivers to sell unused diabetic test strips, continuous glucose monitors (CGMs), lancets, and other diabetic products online.By...

Read more

Glow Sauna Studios Arrives in Illinois with Multi-Unit Award, Bringing Premium Infrared & Light Therapies to the Chicagoland Area

September 10, 2025 11:00 AM

Glow Sauna Studios, one of the nation's fastest-growing wellness brands specializing in premium full-spectrum infrared sauna and red light therapy, is excited to announce a multi-unit expansion into Illinois with its first location opening in north Chicago. This milestone marks a major step in the brand's growth across the Midwest as it continues to bring elevated wellness experiences to new communities. Infrared saunas are a treasure of...

Read more

Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets

September 10, 2025 10:30 AM

Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic milestone towards expanding its commercial footprint and building significant shareholder value. The company has filed a new Provisional Patent (#63/877,517) that embodies a groundbreaking method for loading Extracellular Vesicles (EVs). This technological innovation is poised to give the company a...

Read more

MDCE Subsidiaries Generate Over $1 Million in Revenue Before Close of Q3, Paving Way for Debt-Free Growth and AI Healthcare Advancements

September 10, 2025 9:11 AM

Medical Care Technologies, Inc. (OTC PINK:MDCE) (www.medicalcaretechnologies.com), an emerging innovator in AI-driven health screening technologies, today announced that its subsidiaries, Infinite Auctions and Real Game Used (RGU), have collectively generated $1,012,019 in revenue prior to the close of Q3 2025.Infinite Auctions revenue highlights include a landmark inventory sale of a LeBron James Game-Worn NBA Finals jersey, which sold for...

Read more

Virtual Hybrid Home Care Model Poised to Open 50% More Market Share for Private Duty Home Care Agencies

September 10, 2025 9:00 AM

Private Duty Home Care providers are on the verge of a breakthrough with the launch of the Virtual Hybrid Home Care Model, powered by Addison Care. By combining 24/7 virtual care technologies with an optimized cadence of live visits, agencies can now profitably serve Middle America - dramatically expanding their addressable market from the current 5% of households who can afford traditional hourly care, to over 50% of the U.S. population.The...

Read more

Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025

September 10, 2025 9:00 AM

Genprex, Inc.'s President and Chief Executive Officer, Ryan Confer, will present at the Investor Summit Virtual on September 16, 2025, offering investors an inside look at the company's growth strategies and market opportunities.About Genprex, Inc.Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer...

Read more

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

September 10, 2025 8:00 AM

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and distribution of over-the-counter (OTC) pharmaceutical dermatology focused products that can be sold directly to consumers. This decision was informed by the knowledge gained while developing the Company's Spongilla technology as well as...

Read more

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

September 10, 2025 7:20 AM

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, will host a corporate update webcast/conference call (details below) at 8:30 am Eastern Time to review groundbreaking activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of...

Read more